Global BCG Tuberculosis (TB) Vaccine Market Size By Type (Immune BCG, Therapy BCG), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global BCG Tuberculosis (TB) Vaccine Market was valued at USD 51.2 million in 2023 and is projected to surpass USD 83.7 million by 2031, growing at a CAGR of 6.4% during the forecast period from 2023 to 2031. The market is primarily driven by the ongoing global efforts to eliminate tuberculosis, especially in high-burden countries, along with increasing awareness, childhood immunization programs, and the expanding reach of universal health coverage. BCG (Bacillus Calmette–Guérin) remains the only licensed vaccine for TB prevention and plays a critical role in infant and pediatric TB control worldwide.

Drivers:

1. Global TB Eradication Initiatives:

Organizations like WHO, GAVI, and UNICEF are actively promoting universal BCG immunization, especially in regions with high TB incidence. This global momentum is significantly boosting demand for the vaccine.

2. Rising Infant Immunization Rates:

Many countries have integrated BCG vaccination into their national immunization schedules, ensuring almost universal coverage among newborns, especially in Asia-Pacific and Africa.

3. High TB Burden in Developing Nations:

Endemic regions with poor sanitation and healthcare access continue to show high TB prevalence, prompting mass immunization efforts and propelling the BCG vaccine market.

Restraints:

1. Limited Efficacy in Adult Pulmonary TB:

Although effective in preventing severe forms of childhood TB, BCG has limited efficacy in adults for pulmonary TB, which constitutes a large part of the disease burden.

2. Supply Chain Disruptions:

BCG vaccines require cold chain logistics and consistent manufacturing quality. Supply bottlenecks and regulatory challenges can hinder vaccine availability, especially in remote regions.

Opportunity:

1. Research on BCG Revaccination and Novel Applications:

Ongoing research into BCG revaccination and its potential role in enhancing immune responses to other infections is gaining traction. Additionally, its non-specific immune-boosting effects (trained immunity) present broader applications.

2. Expansion of Immunization Programs in Emerging Economies:

As healthcare access improves in low-income and middle-income countries, expanded childhood immunization coverage is expected to significantly increase demand for BCG vaccines.

Market by System Type Insights:

By vaccine type, Lyophilized BCG Vaccine dominated the market in 2023. Lyophilized formulations offer longer shelf-life, better stability during transport, and ease of storage in national immunization programs, especially in low-resource settings.

Market by End-use Insights:

Public Health Sector was the leading end-use segment, accounting for more than 70% of the market share in 2023. Governments and international health organizations procure the majority of BCG vaccines for large-scale infant immunization campaigns, making this sector the key revenue contributor.

Market by Regional Insights:

Asia-Pacific held the largest market share in 2023, driven by high birth rates, government-backed TB control programs, and strong participation in global health alliances. Countries like India, China, Indonesia, and Bangladesh are major contributors. Africa is also projected to witness rapid growth due to increasing healthcare access and donor-funded immunization programs.

Competitive Scenario:

Key players in the Global BCG TB Vaccine Market include Serum Institute of India Pvt. Ltd., AJ Vaccines, Japan BCG Laboratory, GreenSignal Bio Pharma Pvt Ltd, and InterVax Ltd. These companies are focusing on capacity expansion, WHO prequalification, and collaborations with global health bodies to secure large-volume supply contracts. For instance:

Serum Institute of India expanded its lyophilized BCG production capacity in 2024 to meet rising demand across Asia and Africa.

AJ Vaccines collaborated with WHO in 2023 to streamline BCG distribution channels to underserved regions.

GreenSignal Bio Pharma entered into a procurement agreement with GAVI in 2025 for mass supply to sub-Saharan Africa.

Scope of Work – Global BCG Tuberculosis (TB) Vaccine Market

Key Market Developments:

2024: Serum Institute of India announced the development of a new high-efficiency lyophilized BCG vaccine variant with improved immunogenicity for infants in TB-endemic regions.

2023: Japan BCG Laboratory secured extended WHO prequalification, allowing expanded exports to Africa and Southeast Asia.

2025: GreenSignal Bio Pharma signed a strategic agreement with GAVI to supply 10 million doses annually to global immunization campaigns.

FAQs:

1) What is the current market size of the Global BCG Tuberculosis (TB) Vaccine Market?

The market was valued at USD 51.2 million in 2023.

2) What is the major growth driver of the Global BCG Tuberculosis (TB) Vaccine Market?

The key driver is the growing emphasis on universal infant immunization and global TB eradication initiatives.

3) Which is the largest region during the forecast period in the Global BCG Tuberculosis (TB) Vaccine Market?

Asia-Pacific leads the market, driven by high birth rates and strong governmental immunization programs.

4) Which segment accounted for the largest market share in the Global BCG Tuberculosis (TB) Vaccine Market?

The Lyophilized BCG Vaccine segment accounted for the largest share in 2023.

5) Who are the key market players in the Global BCG Tuberculosis (TB) Vaccine Market?

Leading companies include Serum Institute of India, AJ Vaccines, Japan BCG Laboratory, GreenSignal Bio Pharma, and InterVax Ltd.